BR112022002797A2 - Otimização de formulação para anticorpos biespecíficos - Google Patents

Otimização de formulação para anticorpos biespecíficos

Info

Publication number
BR112022002797A2
BR112022002797A2 BR112022002797A BR112022002797A BR112022002797A2 BR 112022002797 A2 BR112022002797 A2 BR 112022002797A2 BR 112022002797 A BR112022002797 A BR 112022002797A BR 112022002797 A BR112022002797 A BR 112022002797A BR 112022002797 A2 BR112022002797 A2 BR 112022002797A2
Authority
BR
Brazil
Prior art keywords
bispecific antibodies
formulation
formulation optimization
optimizing
systems
Prior art date
Application number
BR112022002797A
Other languages
English (en)
Inventor
Zhou Chen
Wang Wenhua
Liu Dingjiang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112022002797A2 publication Critical patent/BR112022002797A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

OTIMIZAÇÃO DE FORMULAÇÃO PARA ANTICORPOS BIESPECÍFICOS. A presente invenção fornece métodos e sistemas para otimização de formulação de anticorpos biespecíficos. O presente pedido também fornece métodos e sistemas para selecionar candidatos a moléculas para a construção de anticorpos biespecíficos e otimização da formulação dos mesmos. Os parâmetros físico-químicos de um anticorpo biespecífico são caracterizados. As estratégias de otimização da formulação são guiadas pela predição de parâmetros de interação. Várias estratégias de otimização de formulação são fornecidas com base nestes parâmetros físico-químicos.
BR112022002797A 2019-08-20 2020-08-20 Otimização de formulação para anticorpos biespecíficos BR112022002797A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962889354P 2019-08-20 2019-08-20
PCT/US2020/047156 WO2021035028A2 (en) 2019-08-20 2020-08-20 Formulation optimization for bispecific antibodies

Publications (1)

Publication Number Publication Date
BR112022002797A2 true BR112022002797A2 (pt) 2022-08-09

Family

ID=72322561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002797A BR112022002797A2 (pt) 2019-08-20 2020-08-20 Otimização de formulação para anticorpos biespecíficos

Country Status (11)

Country Link
US (1) US20210054050A1 (pt)
EP (1) EP4017877A2 (pt)
JP (1) JP2022544818A (pt)
KR (1) KR20220047611A (pt)
CN (1) CN114787629A (pt)
AU (1) AU2020332821A1 (pt)
BR (1) BR112022002797A2 (pt)
CA (1) CA3151337A1 (pt)
IL (1) IL290690A (pt)
MX (1) MX2022002110A (pt)
WO (1) WO2021035028A2 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106519025B (zh) * 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CN111402950B (zh) * 2013-11-29 2024-03-19 豪夫迈·罗氏有限公司 抗体选择装置和方法
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies

Also Published As

Publication number Publication date
CN114787629A (zh) 2022-07-22
CA3151337A1 (en) 2021-02-25
MX2022002110A (es) 2022-05-18
KR20220047611A (ko) 2022-04-18
WO2021035028A3 (en) 2021-04-08
US20210054050A1 (en) 2021-02-25
WO2021035028A2 (en) 2021-02-25
IL290690A (en) 2022-04-01
EP4017877A2 (en) 2022-06-29
JP2022544818A (ja) 2022-10-21
AU2020332821A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
AR106199A1 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
BR112017014308A2 (pt) anticorpos biespecíficos contra calicreína plasmática e fator xii
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
BR112019000770A2 (pt) proteínas de ligação semelhantes a anticorpos biespecíficos que se ligam especificamente às cd3 e cd123
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
BR112022011669A2 (pt) Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
BR112021025438A2 (pt) Composições de proteínas anti-vegf e métodos para produzir as mesmas
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
BR112022002797A2 (pt) Otimização de formulação para anticorpos biespecíficos
BR112019006624A2 (pt) método de multiprotease
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra